Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Steve brings deep experience in strategic transactions to Werewolf at this critical time,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. “Werewolf is ...

NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease. The decision, prompted by a ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

LONDON - The Sage Group (LON:SGE) plc, a market leader in finance, HR, and payroll software, announced on Thursday the appointment of its CEO Steve Hare as an independent non-executive director at ...

Plus Therapeutics shares are trading higher by 244% during Thursday's session. The company announced that the FDA accepted the name REYOBIQ for the company's lead asset. Feel unsure about the ...

Xero vs Sage: Best Accounting Software for 2025? Your email has been sent Here’s my comparison of Xero vs Sage and determine which software suits your business’ accounting and financial ...